# A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL

> **NCT02323230** · PHASE2 · TERMINATED · sponsor: **ImmunoVaccine Technologies, Inc. (IMV Inc.)** · enrollment: 4 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** DPX-Survivac
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02323230
- **Lead sponsor:** ImmunoVaccine Technologies, Inc. (IMV Inc.)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01
- **Primary completion:** 2017-06
- **Final completion:** 2018-02
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** new study
- **Last updated:** 2021-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02323230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02323230, "A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT02323230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*